Abstract
The Diabetic Retinopathy Study (DRS) assessed the ability of photocoagulation to delay or prevent severe visual loss in people with proliferative diabetic retinopathy. Benefit was detected early, but there where concerns about the possibility of late adverse effects. Calculations using projected blindness and death rates reassured the data monitoring committee that even large late adverse affects would not offset the early benefit already observed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ederer F, Podgor MJ, and The Diabetic Retinopathy Study Research Group. 1984. Assessing possible late effects of in stopping a clinical trial early: A case study. Diabetic Retinopathy Study Report No. 9. Control Clin Trials 5:373–381.
Ederer F, Hiller R. 1975. Clinical trials, diabetic retinopathy, and photocoagulation: A reanalysis of five studies. Surv Ophthalmol 19:267–286.
The Diabetic Retinopathy Study Research Group. 1981. Diabetic Retinopathy Study Report Number 6: Design, methods, and baseline results. Invest Ophthalmol Vis Sci 21:149–209.
The Diabetic Retinopathy Study Research Group. 1976. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81:383–396.
Francois J, DeLaey JJ, Cambie E, Hanssens M, Victoria-Troncoso V. 1975. Neovascularization after argon laser photocoagulation of macular lesions. Am J Ophthalmol 79:206–210.
Davis MD, Hiller, R, Magli YL, Podgor MJ, Ederer F, Harris W A, et al. 1979. Prognosis for life in patients with diabetes: Relation to severity of retinopathy. Trans Am Ophthalmol Soc LXXVII:144–170.
Cutler SJ, Ederer F. 1958. Maximum utilization of the life table method in analyzing survival. J Chronic Dis 8:699–712.
Bayo F. United States Life Tables by Causes of Death: 1959–61, Vol 1, No. 6, National Center for Health Statistics, Public Health Service Publication No. 1252, U.S. Dept. HEW, Washington, DC, May 1968.
Berg JW. 1964. Disease-oriented end results. A tool for pathological clinical analysis. Cancer 17:693–707.
Ederer F, Podgor MJ. 1978. Estimates of a hypothetical delayed deleterious effect of photocoagulation treatment for diabetic retinopathy. Office of Biometry and Epidemiology. National Eye Institute. Biometrics Note No. 6, February.
The Coronary Drug Project Research Group. 1981. Practical aspects of decision making in clinical trials: The Coronary Drug Project as a case study. Control Clin Trials 1:367–376.
The Diabetic Retinopathy Study Research Group. Unpublished data
The Diabetic Retinopathy Study Research Group. 1978. Photocoagulation treatment of proliferative diabetic retinopathy. The second report of the Diabetic Retinopathy Study. Ophthalmology 85:82–106.
The Diabetic Retinopathy Study Research Group. 1981. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings. DRS Report Number 8. Ophthalmology 88:583–600.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Ederer, F. (2006). Assessing Possible Late Treatment Effects Early: The Diabetic Retinopathy Study Experience. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_5
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_5
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)